Animal models show GLP1 receptor agonists delay memory decline GLP1 receptor agonists slow down memory decline in patients with type 2 diabetes and prevent glucose transport decline through BBB in AD patients A phase IIb clinical trial evaluating a GLP1 analog demonstrated improved cognitive function and MRI volume A phase III clinical trial evaluating a GLP1 analog is ongoing. The gene discussed is GLP1R; the disease is Alzheimer disease.